Teleflex (TFX) Q2 FY26 earnings call

Teleflex delivered better-than-expected Q2 FY26 revenue and EPS, driven by robust performance in its Vascular and Surgical segments. However, the Interventional business faced integration challenges post-acquisition, leading to a revised full-year revenue outlook. The company is actively executing strategic divestitures and capital allocation plans, including significant share repurchases and debt reduction, with management anticipating substantial financial performance improvements in 2027 and beyond.